Get the Stockscreener App
53.72
1.76%
-0.96
Pre-market:
53.24
-0.48
-0.89%
Moderna Inc stock is traded at $53.72, with a volume of 13.56M.
It is down -1.76% in the last 24 hours and down -0.39% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$54.68
Open:
$55.7
24h Volume:
13.56M
Relative Volume:
1.34
Market Cap:
$21.30B
Revenue:
$1.94B
Net Income/Loss:
$-2.82B
P/E Ratio:
-7.3977
EPS:
-7.2617
Net Cash Flow:
$-2.08B
1W Performance:
+5.42%
1M Performance:
-0.39%
6M Performance:
+106.54%
1Y Performance:
+117.36%
1-Day Range:
$52.95
$56.06
1-Week Range:
$50.05
$56.06
52-Week Range:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
53.72 | 21.30B | 1.94B | -2.82B | -2.08B | -7.2617 |
VRTX
Vertex Pharmaceuticals Inc
|
441.20 | 112.22B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.57 | 79.35B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
849.04 | 52.80B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.66 | 41.32B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
323.87 | 35.95B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Study shows Sanofi's Nuvaxovid better tolerated than Moderna's mNEXSPIKE - marketscreener.com
Moderna Inc stock (US60770K1079): Is the post-COVID pivot strong enough to unlock sustained upside? - AD HOC NEWS
Moderna Impfstoff (Spikevax): Respiratory Pivot Amid Vaccine Demand Shifts - AD HOC NEWS
Moderna Inc. stock (US60770K1034): Is its mRNA pivot beyond COVID strong enough for sustained growth - AD HOC NEWS
Moderna’s mRNA Melanoma Data And Fast Track Status Shape Oncology Story - Yahoo Finance
Behavioral Patterns of MRNA and Institutional Flows - Stock Traders Daily
Communiqué de presse : ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directe - GlobeNewswire Inc.
Moderna (MRNA) Advances Cancer Therapy Research with Promising D - GuruFocus
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting - Investing News Network
Moderna’s melanoma therapy shows 83% response rate in trial By Investing.com - Investing.com Canada
Moderna’s melanoma therapy shows 83% response rate in trial - Investing.com
In 12 melanoma patients, Moderna combo posted 83% response - Stock Titan
Goldman Sachs Adjusts Moderna Price Target to $43 From $41, Maintains Neutral Rating - marketscreener.com
Kailera Therapeutics secures $625M in IPO, surpassing Moderna's 2018 debut - The Business Journals
What Moderna (MRNA)'s Expedited Flu Vaccine Review And Institutional Support Means For Shareholders - Yahoo Finance
MRNA Stock Quote Price and Forecast - CNN
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026 - Investing News Network
Moderna to Report Q1 2026 Financial Results - National Today
NSCLC Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | AbbVie, AstraZeneca and Daiichi Sankyo, Shanghai Henlius Biotech, Moderna Therapeutics/ Merck, BeyondSpring, Cullinan - Barchart
Moderna: The Case For Staying On The Sidelines - Seeking Alpha
COVID-19 mRNA-1273 Vaccination Not Linked to Increased cTnI Levels in Youth - Vaccine Advisor
Moderna Inc. stock (US60770K1034): Is its mRNA platform strong enough to unlock new upside? - AD HOC NEWS
Moderna Impfstoff (Spikevax): Pivot to Cancer Vaccines Reshapes Future - AD HOC NEWS
OS Therapies Appoints Moderna Co-Founder to Strategic Advisory Board - National Today
Moderna Inc. stock (US60770K1034): Is mRNA pipeline expansion strong enough to unlock new upside? - AD HOC NEWS
3 Unpopular Stocks We Approach with Caution - The Globe and Mail
MRNA SEC FilingsModerna 10-K, 10-Q, 8-K Forms - Stock Titan
Moderna Inc. stock (US60770K1034): Is the pivot beyond COVID vaccines now the real test? - AD HOC NEWS
Moderna Impfstoff (Spikevax): Respiratory Vaccine Pivot Could Reshape mRNA Future - AD HOC NEWS
Moderna (MRNA) Sees Positive Momentum with Earnings Ahead - GuruFocus
Moderna Impfstoff (Spikevax): mRNA Pivot Beyond COVID Fuels Uncertain Path - AD HOC NEWS
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate - Milwaukee Journal Sentinel
Baillie Gifford & Co. Sells 1,266,152 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Stock (MRNA) Opinions on FDA Flu Vaccine Review - Quiver Quantitative
Best Biotech Stocks To Keep An Eye OnApril 12th - MarketBeat
Segovias de Estelí Returns to Germany via Tradición Moderna, Announces InterTabac Exclusive Release - halfwheel
Moderna Target of Unusually High Options Trading (NASDAQ:MRNA) - MarketBeat
Promising Biotech Stocks To Follow TodayApril 10th - MarketBeat
Moderna, Inc. $MRNA Shares Bought by Douglas Lane & Associates LLC - MarketBeat
What is behind Moderna stock's recent drop in value today - Traders Union
Moderna Inc (MRNA) Stock Price Quote Today & Current Price Chart - Capital.com
MODERNA, INC. (MRNA) - MSN
Moderna (MRNA) Experiences Bullish Trading Activity - GuruFocus
Moderna Flu And RSV Data Highlight Push Beyond COVID And Valuation Tension - Yahoo Finance
Moderna Is Most Shorted S&P 500 Stock Now. Is It a Contrarian Buy? - Barchart.com
Moderna eyes international markets as growth driver, says Bank of America - Proactive financial news
Moderna, Inc. (MRNA) stock price, news, quote and history - Yahoo Finance UK
(MRNA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Messenger RNA (mRNA) Market Projected to Reach $20.99 - GlobeNewswire
Messenger RNA (mRNA) Market Projected to Reach $20.99 Billion by 2035Moderna, Pfizer, and Others Propel mRNA Expansion into New Therapeutic Areas - Yahoo Finance
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.19%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):